Celltrion shares rose nearly 8% on Tuesday, following news that an Italian COVID-19 patient tested negative for SARS-CoV-2 a week after being treated with the company's autoimmune disease treatment Remsima, reported The Korea Herald.
Celltrion said the patient who had symptoms of pneumonia due to SARS-CoV-2 infection, was treated with Remsima, and was discharged a week later after recovery. The patient had pre-existing ulcerative colitis.
The findings were published in the journal Gut. The TNF-alpha drug, used to treat inflammatory bowel disease and rheumatoid arthritis, is currently undergoing trials on COVID-19 patients to test if it will show therapeutic effects against the coronavirus.
To read more NewsPoints articles, click here.